文献支持

大小鼠喉镜/小鼠喉镜/大鼠喉镜

价格询价

品牌Penn-Century
货号Penn-Century
更新日期2026年05月01日

北京元森凯德生物技术有限公司

7 年金牌会员

相关产品推荐更多 >

万千商家帮你免费找货

0 人在求购买到急需产品

详细信息
询价记录
文献和实验
技术资料

保修期：
12个月
现货状态：
现货

本款产品专门为喉部检查或操作的高端高清WIFI可视喉镜，产品内置wifi功能，通过前端的摄像头，在iPhone、iPad、android具备无线网络连接功能的手机上可清晰观察喉部等结构，方便进行肺部给药，操作简单，是气管插管等实验操作中不可缺少的工具。
产品细节图片1

附：北京元森凯德生物技术有限公司2013年成立于北京中关村科技园，是一家专业从事生命科学类实验仪器研制、生产与销售的科技创新型企业。服务毒理学、药理学、免疫学、生物安全、大气污染物、化学物质毒性鉴定、临床前药物开发与安全性评价、呼吸系统、环境与健康等领域。

元森凯德在中国北京、美国宾夕法尼亚均设有技术联络中心，注重仪器的售前、售中、售后沟通，时刻关注行业的新进展动态，客户群体主要有全国各大高校、实验动物科研单位、药物研发机构、第三方CRO及医院中心实验室等。我们将以领先的技术、优质的产品、完善的服务致力于成为业内优秀的实验仪器设备供应厂商。

我们的目标是：服务用户至上，让科研仪器的使用变得更简便和高效。

风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

作者 内容 询问日期

文献和实验

该产品被引用文献

Received: 27 November 2024 / Accepted: 10 March 2025

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a rare and serious chronic interstitial lung disease that may endanger the lives of patients.

The median survival time of patients with idiopathic pulmonary fbrosis is short, and the mortality rate is higher than that of

many types of cancer. At present, pirfenidone (PFD) and nintedanib (NDNB) have been approved by FDA for IPF, but they can

only delay the process of pulmonary fbrosis and cannot cure the disease. Therefore, it is urgent to develop other drugs with the

efect of improving pulmonary fbrosis. Ellagic acid (EA) can inhibit the Wnt-signaling pathway and has an efect in treating

pulmonary fbrosis induced by bleomycin (BLM) in mice. However, its solubility is poor, resulting in its low bioavailability

and limited therapeutic benefts, so its clinical application has been limited. Herein, based on the characteristics of nano-drug

lung delivery system, chitosan (CS) was selected as the carrier, and ellagic acid-loaded chitosan nanoparticles (EA-CS-NPs)

were prepared by ionic gelation method. The EE% and DL% of prepared EA-CS-NPs was 73.73±4.52% and 6.23±1.09%,

the particle size was 119.6±5.51 nm (PDI=0.234±0.017), the zeta potential was 29.833±0.503 mV. The morphology of the

nanoparticles was observed by TEM microscope, which was round, uniform dispersion, indicating that the preparation process

is stable and feasible. The toxicity experiment showed that EA-CS-NPs maintained 80% cell viability, signifcantly higher than

that of the NDNB group, indicating lower toxicity and better inhibitory efects on TGF-β1-stimulated MLg and NIH-3T3 cells.

Wound healing assay results showed that the inhibitory efect of EA-CS-NPs on cell migration was more pronounced than that

of EA in the same amount of EA-containing drugs. Drug uptake experiments revealed that EA-CS-NPs signifcantly enhanced

drug uptake in MLg and NIH-3T3 cells. In vivo, Cy7-CS-NPs exhibited higher fuorescence intensity in rat lungs compared to

Cy7 solution, indicating better lung retention. The in vivo efcacy test showed that compared with the EA group, EA-CS-NPs

could better reduce the area of pulmonary fbrosis and collagen deposition, improve lung function, and have a longer retention

time in the lung. In summary, our results revealed that EA-CS-NPs may be a good choice for the treatment of pulmonary fbrosis.

Keywords chitosan nanoparticle · ellagic acid · intratracheal instillation · pulmonary fbrosis

Introduction

Idiopathic pulmonary fbrosis (IPF) is a severe, progressive

lung disease with an unclear cause, which may endanger the

lives of patients. Its clinicopathological manifestations are

mainly abnormal activation and proliferation of lung fbro

blasts, resulting in continuous deposition of lung extracel

lular matrix, which seriously impairs the lung function of

patients and threatens the lives of patients [1–4]. The data

showed that the prevalence of social idiopathic pulmonary

fbrosis can reach 0.33–4.51 per 10,000 people today [5–7].

It is relatively high and rising year by year. It is not opti

mistic that the median survival of patients with idiopathic

pulmonary fbrosis is less than 3 years, and the mortality

rate is even higher than that of many types of cancer [8–10].

At present, two drugs have been approved by the FDA

for the treatment of idiopathic pulmonary fbrosis, namely

pirfenidone (PFD) and nintedanib (NDNB) [11–13]

相关实验

急性会厌炎
　急性会厌炎是由病毒和细菌引起的会厌急性感染，也可由变态反应、物理、化学剌激引起。起病急，发展快，易引起上呼吸道阻塞。临床表现　　1.突然咽喉疼痛，咽喉堵塞感，重者发冷发热，吞咽困难及呼吸困难。 2.咽部检查正常，压舌根向下压可见高度红肿的会厌。 3.甲状X骨外缘压痛。诊断依据　　1.咽喉痛疼伴阻塞感，发冷发热，吞咽困难。 2.压舌根向下见高度红肿的会厌。 3.间接或直接喉镜下见会厌红肿、水肿有时有脓点或溃疡。治疗
喉咽癌
　　喉咽癌系发生在喉咽部的恶性肿瘤，多为鳞癌常见于５０岁以上女性，由于位置隐匿，不易察觉，且可侵犯邻近组织，预后差。临床表现　　1.咽部异物感或吞咽痛疼、吞咽困难。 2.呛咳、咳血。 3.声嘶、呼吸困难。 4.口臭。 5.颈淋巴结转移肿大。诊断依据　　1.有上述症状一项或几项同时存在。 2.喉镜或食道镜检查下咽部有肿物呈菜花型、溃疡型、浸润型，表面可有坏死或出血，梨状窝有唾液潴留。 3.甲状X骨受侵犯可见外形不对称变宽。颈淋巴结转移时
脑下垂体腺瘤手术的麻醉
②有条件者术前应行颈部x线片检查，了解喉部有无钙化，声门有无狭窄。 ③部分病人虽然会厌大、喉粘膜肥厚，但声门大显露并不困难。 ④部分病人表现为舌头大、会厌小，喉头既固定其入口又小，喉镜显露及气管内插管均困难，宜于清醒下气管内插管或采用光导纤维喉镜。 ⑤如病人舌及会厌大则需准备大型喉镜，有时需要两个大喉镜片同时放入才能显露声门完成气管内插管。（2）生长激素可促进肝脏输出葡萄糖，抑制周围组织利用糖，故肢端肥大症患者可伴有糖尿病及酮血症，术前应